GSGabrielle Schmidt

Gabrielle Schmidt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabrielle Schmidt has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ATG exposure in T replete transplant for hematological malignancies: Real world analysis from BMT CTN 1202

    by Madhavi Lakkaraja, Audrey Mauguen, Kinga Hosszu, Devin McAvoy, Valerie Stewart, Gabrielle Schmidt, John E. Levine, Miguel-Angel Perales, Sergio A. Giralt, K. Scott Baker, et al.

    Traditional weight-based dosing results in variable rabbit anti-thymocyte globulin (rATG) clearance, delaying CD4+Tcell-immune-reconstitution (CD4 + IR) and impacting outcomes. In a retrospective pharmacokinetic/pharmacodynamic analysis of patients undergoing first T-replete hematopoietic cell transplantation (HCT), enrolled on BMT CTN 1202, we estimated post-HCT rATG-exposures as area under the curve (arbitrary unit per day/milliliter [AUxd/mL]) using a validated pharmacokinetic-model. Results were compared to patients who did not receive rATG. Previously defined post-HCT rATG-exposure groups: A: < 30, B:30-55 and C: ≥ 55 AUxd/mL were correlated with outcomes of interest using cox-proportional-hazard and cause-specific-hazards models. 325 patients (median age 51 years) were included: 228 received rATG. Median post-HCT rATG-exposure was 44.1 (Range 6.2–125.0). Among patients who received rATG, higher exposure correlated with worse five-year overall survival (OS) (no-ATG:51%; group A:67%; B:49%; C:34%, p = 0.01), higher five-year relapse incidence (no-ATG:31%; A:27%; B: 42%; C: 58%, p < 0.001) and lower CD4 + IR (no-ATG:64%; A:73%; B:51%; C:19%, p = 0.001). Grade 2-4 acute graft versus host disease (GVHD) rates were: no-ATG:40% ; A:26%, B:39%, C:35%, (p = 0.44). Any rATG-exposure was associated with lower moderate/severe chronic GVHD (HR:0.63, p = 0.025). Low post-HCT rATG-exposure ( < 30AUxd/mL) but not absent correlated with higher OS, lower relapse, and lower GVHD related deaths. Model-based-dosing could be used to target optimal post-HCT rATG-exposure and improve HCT outcomes.

  • Open Access

    ATG Exposure in T Replete Transplant for Hematological Malignancies: Real World Analysis from BMT CTN 1202

    by Jaap Jan Boelens, Madhavi Lakkaraja, Audrey Mauguen, Kinga Hosszu, Devin McAvoy, Valerie Greco-Stewart, Gabrielle Schmidt, John Levine, Miguel Angel Perales, Sergio A. Giralt, et al.

    Traditional weight-based dosing results in variable rabbit anti-thymocyte globulin (rATG) clearance, delaying CD4 + Tcell-immune-reconstitution (CD4 + IR) and impacting outcomes. In a retrospective pharmacokinetic/pharmacodynamic analysis of patients undergoing first T-replete hematopoietic cell transplantation (HCT), enrolled on BMT CTN 1202, we estimated post-HCT rATG-exposures as area under the curve (arbitrary unit per day/milliliter [AUxd/mL]) using a validated pharmacokinetic-model. Results were compared to patients who did not receive rATG. Previously defined post-HCT rATG-exposure groups: A:<30, B:30–55 and C:≥55 AUxd/mL were correlated with outcomes of interest using cox-proportional-hazard and cause-specific-hazards models. 325 patients (median age 51 years) were included: 228 received rATG. Median post-HCT rATG-exposure was 44.1 (Range 6.2–125.0). Among patients who received rATG, higher exposure correlated with worse five-year overall survival (OS) (no-ATG:51%; group A:67%; B:49%; C:34%, p = 0.01), higher five-year relapse incidence (no-ATG:31%; A:27%; B: 42%; C: 58%, p < 0.001) and lower CD4 + IR (no-ATG:64%; A:73%; B:51%; C:19%, p = 0.001). Grade 2–4 acute graft versus host disease (GVHD) rates were: no-ATG:40% ; A:26%, B:39%, C:35%, (p = 0.44). Any rATG-exposure was associated with lower moderate/severe chronic GVHD (HR:0.63, p = 0.025). Low post-HCT rATG-exposure (< 30AUxd/mL) but not absent correlated with higher OS, lower relapse, and lower GVHD related deaths. Model-based-dosing could be used to target optimal post-HCT rATG-exposure and improve HCT outcomes.

  • Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis

    by Nosha Farhadfar, Stephanie Bo-Subait, Gabrielle Schmidt, Brent Logan, Mahmoud Aljurf, Sherif Badawy, Amer Beitinjaneh, Lohith Gowda, Kimberly A. Kasow, Matthew Seftel, et al.


  • Open Access

    Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends

    by Danh T. Tran, Ruyun Jin, Hong Zhu, Gabrielle Schmidt, Stephen R. Spellman, Karen K. Ballen

    Randomized clinical trials are expensive and not always practice changing. The Blood and Marrow Transplant Clinical Trials Network (CTN) 1101 trial (2012–2018) showed a lower two-year overall survival after umbilical cord blood (UCB) compared to haploidentical graft (haplo) transplants. To quantify the change in graft utilization after the trial’s publication, a cohort of 11,190 U.S. adult HCT recipients selected with inclusion/exclusion criteria similar to CTN-1101’s were analyzed across three time periods: 2010–2012 (pre-study), 2013–2018 (during-study), and 2019–2022 (post-study). We found a significant increase in haplo utilization compared to UCB, with the trend beginning around 2013. Compared to non-Hispanic White, Black recipients were more likely to receive haplo, Asian recipients were less likely, and Hispanic recipients had similar rates. We also expanded our analyses to 61,465 patients to assess haplo and UCB utilization compared to other allogeneic donors. In this cohort, utilization of alternative donor grafts increased when compared to HLA-matched related or unrelated donor grafts for Black, Hispanic, and Asian recipients. Our findings demonstrate practice change toward haplo transplants had begun before the CTN-1101 trial’s publication and continued to significantly increase afterward. HLA-mismatched donors are vital alternative graft sources, allowing patients of all backgrounds to receive HCT.